Why imatinib remains an exception of cancer research

Journal of Cellular Physiology

Volumn 228, Issue 4, 2013, Pages 665-670

  Horne, Steven D ^a   Stevens, Joshua B ^a   Abdallah, Batoul Y ^a   Liu, Guo ^a   Bremer, Steven W ^a   Ye, Christine J ^a   Heng, Henry H Q ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; FUSION GENE; HUMAN; KARYOTYPE EVOLUTION; MOLECULAR EVOLUTION; POPULATION STRUCTURE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

EID: 84871698081     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24233     Document Type: Short Survey

References (79)

1. Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34:369-376.
2. Assouline S, Lipton JH. 2011. Monitoring response and resistance to treatment in chronic myeloid leukemia. Curr Oncol 18:e71-e83.
3. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. 2011. The genomic complexity of primary human prostate cancer. Nature 470:214-220.
4. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238-18242.
5. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. 2005. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23:455-460.
6. Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL. 2008. Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer 114:315-322.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516.
8. de The H, Chen Z. 2010. Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10:775-783.
9. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
11. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
12. Frank SA, Nowak MA. 2004. Problems of somatic mutation and cancer. Bioessays 26:291-299.
13. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. 2009a. Adaptive therapy. Cancer Res 69:4894-4903.
14. Gatenby RA, Brown J, Vincent T. 2009b. Lessons from applied ecology: Cancer control using an evolutionary double bind. Cancer Res 69:7499-7502.
15. Gatenby RA, Gillies RJ, Brown JS. 2010. Evolutionary dynamics of cancer prevention. Nat Rev Cancer 10:526-527.
16. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892.
17. Gerrish PJ, Lenski RE. 1998. The fate of competing beneficial mutations in an asexual population. Genetica 102-103:127-144.
18. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R. 2011. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244.
19. Gillies RJ, Verduzco D, Gatenby RA. 2012. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12:487-493.
20. Gravis G, Bladou F, Salem N, Goncalves A, Esterni B, Walz J, Bagattini S, Marcy M, Brunelle S, Viens P. 2008. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 19:1624-1628.
21. Gu G, Brothman AR. 2011. Cytogenomic aberrations associated with prostate cancer. Cancer Genet 204:57-67.
22. Guérin O, Fischel JL, Ferrero J-M, Bozec A, Milano G. 2010. EGFR targeting in hormone-refractory prostate cancer: Current appraisal and prospects for treatment. Pharmaceuticals 3:2238-2247.
23. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature 344:251-253.
24. Heng HH. 2007. Cancer genome sequencing: The challenges ahead. Bioessays 29:783-794.
25. Heng HH. 2012. Biocomplexity: Challenging reductionism. In: Sturmberg JP, Martin CC, editors. Handbook on systems and complexity in health. Chapter 12. New York: Springer (in press).
26. Heng HH. 2013. 4-D Genomics: The genome dynamics and constraint in evolution. New York: Springer (in press).
27. Heng HH, Stevens JB, Liu G, Bremer SW, Ye CJ. 2004. Imaging genome abnormalities in cancer research. Cell Chromosome 3:1.
28. Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. 2006a. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 98:1424-1435.
29. Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. 2006b. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49:195-204.
30. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. 2006c. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208:461-472.
31. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. 2009. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J Cell Physiol 220:538-547.
32. Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. 2010a. The evolutionary mechanism of cancer. J Cell Biochem 109:1072-1084.
33. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. 2010b. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 11:1304-1316.
34. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. 2011a. Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 98:242-252.
35. Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. 2011b. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 112:217-253.
36. Heng HH, Liu G, Stevens JB, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Ye CJ. 2013. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res (in press).
37. Heppner GH, Miller FR. 1998. The cellular basis of tumor progression. Int Rev Cytol 177:1-56.
38. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196.
39. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. 2009. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 106:3342-3347.
40. Huettner CS, Zhang P, Van Etten RA, Tenen DG. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24:57-60.
41. Jabbour E, Hochhaus A, Cortes J, La Rosee P, Kantarjian HM. 2010. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24:6-12.
42. Johansson B, Fioretos T, Mitelman F. 2002. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76-94.
43. Kaufmann SH. 2006. Imatinib spells BAD news for Bcr/abl-positive leukemias. Proc Natl Acad Sci USA 103:14651-14652.
44. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105-2110.
45. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
46. Losi L, Baisse B, Bouzourene H, Benhattar J. 2005. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26:916-922.
47. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136:823-837.
48. Maley CC, Reid BJ, Forrest S. 2004. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: Simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev 13:1375-1384.
49. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924-935.
50. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG. 2009. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15:4706-4711.
51. Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H. 2003. Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 9:2294-2299.
52. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:90-94.
53. Nishizaki T, Harada K, Kubota H, Furuya T, Suzuki M, Sasaki K. 2002. Chromosome instability in malignant astrocytic tumors detected by fluorescence in situ hybridization. J Neurooncol 56:159-165.
54. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194:23-28.
55. Nowell PC, Hungerford DA. 1960. Minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1497.
56. Petrelli F, Borgonovo K, Cabiddu M, Barni S. 2012. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13 randomized trials. Clin Lung Cancer 13:107-114.
57. Radich JP. 2007. The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program 2007:384-391.
58. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. 2007. Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-1243.
59. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293.
60. Rubin MA, Maher CA, Chinnaiyan AM. 2011. Common gene rearrangements in prostate cancer. J Clin Oncol 29:3659-3668.
61. Sato H, Uzawa N, Takahashi K, Myo K, Ohyama Y, Amagasa T. 2010. Prognostic utility of chromosomal instability detected by fluorescence in situ hybridization in fine-needle aspirates from oral squamous cell carcinomas. BMC Cancer 10:182.
62. Sharma SV, Bell DW, Settleman J, Haber DA. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
63. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. 2011. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012.
64. Skorski T. 2011. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma 52:23-29.
65. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. 2010. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 33:609-613.
66. Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. 2007. Mitotic cell death by chromosome fragmentation. Cancer Res 67:7686-7694.
67. Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Huttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. 2011a. Diverse system stresses: Common mechanisms of chromosome fragmentation. Cell Death Dis 2:e178.
68. Stevens JB, Abdallah BY, Horne SD, Liu G, Bremer SW, Heng HH. 2011b. Genetic and epigenetic heterogeneity in cancer. eLS. Chichester: John Wiley & Sons Ltd. [doi: 10.1002/9780470015902.a0023592].
69. Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SW, Ye KJ, Huang JY, Kurkinen M, Ye CJ, Heng HH. 2013. Heterogeneity of cell death. Cytogenet Genome Res (in press).
70. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
71. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM. 2008. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188.
72. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. 2007. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20:921-928.
73. Valabrega G, Montemurro F, Aglietta M. 2007. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977-984.
74. Vitoux D, Nasr R, de The H. 2007. Acute promyelocytic leukemia: New issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39:1063-1070.
75. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096.
76. Ye CJ, Liu G, Bremer SW, Heng HH. 2007. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118:237-246.
77. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. 2009. Genome based cell population heterogeneity promotes tumorigenicity: The evolutionary mechanism of cancer. J Cell Physiol 219:288-300.
78. Zamecnikova A, Al Bahar S, Elshinnawy SE. 2010. Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient. Leuk Res 34:1617-1621.
79. Zhang Y, Rowley JD. 2011. Chronic myeloid leukemia: Current perspectives. Clin Lab Med 31:687-698, x.